Lumosa Therapeutics Co (ROCO:6535) ROCE %: -14.59% (As of Dec. 2025)


ROCO:6535 Lumosa Therapeutics Co Ltd ROCO:6535
70 GF Score
Price NT$97.00
GF Value NT$130.67
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Lumosa Therapeutics Co ROCE %?

Lumosa Therapeutics Co ROCO:6535 -2.81% 70 ROCE % is -14.59% as of Dec. 2025. GuruFocus rates ROCO:6535 with a GF Score™ of 70/100 and a GF Value™ of NT$130.67 (Modestly Undervalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lumosa Therapeutics Co's annualized ROCE % for the quarter that ended in Dec. 2025 was -14.59%.

Lumosa Therapeutics Co  (ROCO:6535) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lumosa Therapeutics Co ROCE % Related Terms

Lumosa Therapeutics Co ROCE % Historical Data

* Premium members only.

The historical data trend for Lumosa Therapeutics Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumosa Therapeutics Co ROCE % Chart

Lumosa Therapeutics Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.17 -26.58 -16.10 -25.93 -20.08

Lumosa Therapeutics Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -39.45 -22.38 -34.60 -8.45 -14.59
ROCO:6535
70GF Score
Lumosa Therapeutics Co Ltd ROCO:6535
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lumosa Therapeutics Co ROCE % Calculation

Lumosa Therapeutics Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-346.417/( ( (2132.961 - 201.176) + (1650.231 - 131.037) )/ 2 )
=-346.417/( (1931.785+1519.194)/ 2 )
=-346.417/1725.4895
=-20.08 %

Lumosa Therapeutics Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=-227.864/( ( (1732.628 - 128.342) + (1650.231 - 131.037) )/ 2 )
=-227.864/( ( 1604.286 + 1519.194 )/ 2 )
=-227.864/1561.74
=-14.59 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -14.59% mean?
Lumosa Therapeutics Co (ROCO:6535) has a ROCE % of -14.59% as of Dec. 2025.
Is Lumosa Therapeutics Co's ROCE % too high?
Lumosa Therapeutics Co's current ROCE % is -14.59%. Overall, Lumosa Therapeutics Co has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lumosa Therapeutics Co's ROCE % compare to VRTX and REGN?
Lumosa Therapeutics Co's ROCE % of -14.59% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Lumosa Therapeutics Co's current ROCE % is -14.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumosa Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, Lumosa Therapeutics Co (ROCO:6535) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$130.67, compared to a current price of NT$97.00 — trading 25.8% below its estimated fair value. The current ROCE % is -14.59%. Lumosa Therapeutics Co's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Lumosa Therapeutics Co (ROCO:6535), the current ROCE % is -14.59% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lumosa Therapeutics Co (ROCO:6535) Overvalued in 2026?

Based on GuruFocus' analysis, Lumosa Therapeutics Co stock appears to be undervalued. The current stock price of NT$97.00 is trading 25.8% below its estimated GF Value™ of NT$130.67. GuruFocus considers Lumosa Therapeutics Co to be Modestly Undervalued.

Key valuation signals for ROCO:6535:

  • ROCE %: -14.59%
  • GF Value™: NT$130.67 vs. price of NT$97.00 (25.8% below fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the ROCO:6535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lumosa Therapeutics Co Business Description

Address Park Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 11503
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Taiwan and also has a presence in Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology, including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
70GF Score

Get the complete analysis for ROCO:6535

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$97.00
Price
NT$130.67
GF Value